Enteric-Coated Mycophenolate Sodium (EC-MPS)

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

De Novo Kidney Transplantation

Conditions

De Novo Kidney Transplantation

Trial Timeline

Apr 1, 2003 โ†’ Jul 1, 2005

About Enteric-Coated Mycophenolate Sodium (EC-MPS)

Enteric-Coated Mycophenolate Sodium (EC-MPS) is a approved stage product being developed by Novartis for De Novo Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00239018. Target conditions include De Novo Kidney Transplantation.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT00405652Phase 3Completed
NCT00529269ApprovedCompleted
NCT00369278Phase 3Completed
NCT00537862ApprovedCompleted
NCT00267150Phase 3Completed
NCT00149968ApprovedCompleted
NCT00238953ApprovedCompleted
NCT00239083ApprovedCompleted
NCT00149942ApprovedCompleted
NCT00150020ApprovedCompleted
NCT00154206ApprovedCompleted
NCT00154232ApprovedCompleted
NCT00150007ApprovedCompleted
NCT00284921Phase 3Terminated
NCT00240955ApprovedCompleted
NCT00312143ApprovedCompleted
NCT00154245ApprovedCompleted
NCT00239070Phase 3Completed
NCT00239018ApprovedCompleted
NCT00238940Phase 3Completed